Pasireotide

Pasireotide is a synthetic cyclohexapeptide somatostatin analog with high-affinity binding to four of the five somatostatin receptor subtypes: SSTR1, SSTR2, SSTR3, and SSTR5. The broad receptor binding profile distinguishes pasireotide from earlier somatostatin analogs (octreotide and lanreotide) that bind predominantly SSTR2 and SSTR5. Pasireotide has particularly high SSTR5 affinity, which is relevant for the Cushing's disease indication (corticotroph adenomas predominantly express SSTR5) and for the glucose-related side effect profile. Two formulations are available: immediate-release pasireotide diaspartate (Signifor) for twice-daily subcutaneous injection, and pasireotide pamoate (Signifor LAR) for once-monthly intramuscular injection.

The molecule was developed by Novartis from systematic screening of somatostatin analog structures for broader receptor binding profiles. The clinical hypothesis was that tumors resistant to first-generation somatostatin analogs might respond to molecules with broader receptor coverage. The clinical development program addressed two indications: Cushing's disease (where corticotroph adenomas predominantly express SSTR5) and acromegaly (where some pituitary tumors have insufficient SSTR2 expression to respond to octreotide/lanreotide).

Cushing's disease is a rare endocrine disorder caused by an ACTH-secreting pituitary adenoma producing chronic cortisol excess. Untreated Cushing's disease has high morbidity (cardiovascular disease, diabetes, osteoporosis, infections, psychiatric symptoms) and increased mortality. Standard treatment is transsphenoidal surgery, but cure rates are 60 to 80 percent for first surgery, leaving substantial residual disease. Medical therapy options before pasireotide were limited (cabergoline, ketoconazole, metyrapone) and often ineffective. Pasireotide became the first FDA-approved medical therapy with a pituitary-targeted mechanism.

The Approved Indications

Pasireotide is approved for two distinct indications with different formulations.

Cushing's disease (FDA approval December 14, 2012, Signifor). Adults with Cushing's disease for whom pituitary surgery is not an option or has not been curative. The immediate-release formulation is administered as 0.6 mg or 0.9 mg subcutaneously twice daily. Doses are titrated based on cortisol response (urinary free cortisol) and tolerability.

Acromegaly (FDA approval December 15, 2014, Signifor LAR). Adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option. The long-acting formulation is administered as 40 mg or 60 mg intramuscularly every 4 weeks. Doses are titrated based on IGF-1 response and tolerability.

The two indications use different formulations because of different dosing requirements. Cushing's disease requires sustained 24-hour cortisol suppression supported by twice-daily dosing. Acromegaly tolerates the longer-duration depot pharmacokinetics with monthly dosing.

Clinical Evidence Base

Cushing's disease registration trial (Colao et al., NEJM 2012). Phase 3 trial in 162 patients with persistent or recurrent Cushing's disease after pituitary surgery. Pasireotide 0.6 mg or 0.9 mg twice daily versus placebo. The 0.9 mg dose produced normalization of urinary free cortisol in 26 percent of patients at month 6 (versus 13 percent at the lower dose). Significant reductions in clinical signs of Cushing's disease, including blood pressure, weight, LDL cholesterol, and quality of life.

Acromegaly registration trial (PAOLA, Gadelha et al., Lancet Diabetes Endocrinology 2014). Phase 3 trial in patients with inadequately controlled acromegaly on octreotide LAR or lanreotide autogel. Pasireotide LAR 40 mg or 60 mg monthly versus continued first-generation somatostatin analog therapy. Significantly higher proportions achieved biochemical control on pasireotide LAR.

Long-term extension studies. Sustained efficacy and characterized safety patterns over multi-year treatment in both Cushing's disease and acromegaly indications.

Off-label investigations. Limited Phase 2 work in carcinoid syndrome and GEP-NETs has not produced indication expansions. The first-generation somatostatin analogs (lanreotide, octreotide LAR) remain the standard for these tumor types based on stronger efficacy and tolerability profiles.

Pasireotide acts through multiple somatostatin receptor subtypes with different downstream effects.

SSTR5 activation on corticotroph adenomas. This is the central mechanism for the Cushing's disease indication. Corticotroph adenomas predominantly express SSTR5 rather than SSTR2. First-generation somatostatin analogs (octreotide, lanreotide) with SSTR2-dominant binding are largely ineffective in Cushing's disease. Pasireotide's SSTR5 activation reduces ACTH secretion from corticotroph adenoma cells, decreasing cortisol production.

SSTR2 activation on somatotrophs. The acromegaly indication mechanism. Similar to first-generation somatostatin analogs, pasireotide reduces GH secretion through SSTR2 activation. The broader receptor profile may add benefit in somatostatin-resistant acromegaly.

SSTR3 activation. SSTR3 is expressed on multiple cell types. Activation contributes to anti-proliferative effects on tumor cells through pro-apoptotic signaling.

SSTR5 activation on pancreatic beta cells. The dominant mechanism behind the glucose-related side effect profile. SSTR5 activation on insulin-producing beta cells reduces insulin secretion. The reduction is more pronounced than with first-generation somatostatin analogs because of the higher SSTR5 affinity of pasireotide. The result is glucose dysregulation in many treated patients.

SSTR5 activation on incretin-producing cells. Reduces GLP-1 and other incretin hormone secretion, contributing to the glucose dysregulation.

Anti-proliferative effects. Direct anti-proliferative effects on neuroendocrine tumor cells through G-protein-coupled signaling pathways.

The multi-receptor profile is the defining pharmacological feature of pasireotide. The broader binding produces therapeutic effects in tumors that do not respond to SSTR2-selective agents, but also produces the specific glucose dysregulation pattern that requires careful management.

Pasireotide is approved for two distinct indications with different formulations.

Cushing's disease (FDA approval December 14, 2012, Signifor). Adults with Cushing's disease for whom pituitary surgery is not an option or has not been curative. The immediate-release formulation is administered as 0.6 mg or 0.9 mg subcutaneously twice daily. Doses are titrated based on cortisol response (urinary free cortisol) and tolerability.

Acromegaly (FDA approval December 15, 2014, Signifor LAR). Adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option. The long-acting formulation is administered as 40 mg or 60 mg intramuscularly every 4 weeks. Doses are titrated based on IGF-1 response and tolerability.

The two indications use different formulations because of different dosing requirements. Cushing's disease requires sustained 24-hour cortisol suppression supported by twice-daily dosing. Acromegaly tolerates the longer-duration depot pharmacokinetics with monthly dosing.

Regulatory status

United States (FDA). Cushing's disease approval December 14, 2012 (Signifor immediate-release). Acromegaly approval December 15, 2014 (Signifor LAR). Active marketing authorization.

European Union (EMA). Both indications approved through centralized procedure.

WADA status. Pasireotide is on the WADA Prohibited List under section S2 as a GH-suppressing agent. Use in competitive sport is a doping violation.

Compounding. Pasireotide is not on the FDA Category 2 bulks list. Active commercial product status under Novartis.

Pasireotide is approved for two distinct indications with different formulations.

Cushing's disease (FDA approval December 14, 2012, Signifor). Adults with Cushing's disease for whom pituitary surgery is not an option or has not been curative. The immediate-release formulation is administered as 0.6 mg or 0.9 mg subcutaneously twice daily. Doses are titrated based on cortisol response (urinary free cortisol) and tolerability.

Acromegaly (FDA approval December 15, 2014, Signifor LAR). Adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option. The long-acting formulation is administered as 40 mg or 60 mg intramuscularly every 4 weeks. Doses are titrated based on IGF-1 response and tolerability.

The two indications use different formulations because of different dosing requirements. Cushing's disease requires sustained 24-hour cortisol suppression supported by twice-daily dosing. Acromegaly tolerates the longer-duration depot pharmacokinetics with monthly dosing.

The pasireotide safety profile includes the standard somatostatin analog effects plus the specific glucose dysregulation pattern.

Glucose dysregulation. The most clinically significant adverse event. In the Cushing's disease registration trial, hyperglycemia or new-onset diabetes occurred in 73 percent of patients. The mechanism is reduced insulin secretion from pancreatic beta cells (SSTR5 activation) plus reduced incretin hormone secretion. Pre-existing diabetes worsens. New diabetes develops in many patients without prior diabetes. Management requires concurrent diabetes therapy (often insulin or GLP-1 agonists) in a substantial proportion of treated patients. This is the principal management challenge with pasireotide.

Gastrointestinal effects. Class-typical somatostatin analog GI effects: diarrhea, nausea, abdominal pain. Generally mild to moderate.

Cholelithiasis. Gallstones develop in 25 to 30 percent of patients on long-term therapy. Similar mechanism to other somatostatin analogs.

QT prolongation. Mild QT interval increase reported. Generally not clinically significant in patients without other QT risk factors.

Bradycardia. Mild reduction in heart rate.

Hepatic effects. Liver enzyme increases in some patients. Periodic monitoring is recommended.

Adrenal insufficiency (Cushing's disease). With effective cortisol suppression, some patients develop adrenal insufficiency requiring temporary or permanent glucocorticoid replacement.

Injection-site reactions. Common with twice-daily subcutaneous administration (immediate-release) or monthly intramuscular administration (LAR).

The benefit-risk profile requires careful patient selection. The glucose dysregulation can be substantial and requires proactive diabetes management as part of the treatment plan.

The somatostatin analog class has three main commercial products with overlapping but distinct profiles.

Pasireotide vs Octreotide (Sandostatin LAR). Octreotide LAR is the first-generation product with SSTR2-dominant binding. Effective in approximately 50 percent of acromegaly patients. Pasireotide is effective in some octreotide-resistant patients but produces more glucose dysregulation. Octreotide does not have a Cushing's disease indication.

Pasireotide vs Lanreotide (Somatuline Depot). Lanreotide has similar SSTR2/SSTR5 binding to octreotide. Effective in approximately 50 percent of acromegaly patients. Does not have Cushing's disease indication. Pasireotide is the option for somatostatin-resistant disease.

Pasireotide vs Paltusotine. Paltusotine is a newer oral SSTR2-selective agonist approved 2024 by FDA for acromegaly. Different mechanism class (oral, non-peptide). Convenience advantage for SSTR2-responsive disease. Pasireotide retains the advantage for SSTR5-dominant or somatostatin-resistant tumors.

Pasireotide vs Pegvisomant. Pegvisomant is a GH receptor antagonist (different mechanism). Used in acromegaly patients who do not respond to somatostatin analogs. Different side effect profile (liver enzyme increases rather than glucose dysregulation). The two are sometimes combined in difficult-to-control acromegaly.

Pasireotide vs Cushing's disease alternatives. Other Cushing's disease medical therapies include cabergoline (dopamine agonist, modest efficacy), ketoconazole and metyrapone (adrenal steroidogenesis inhibitors), osilodrostat (newer steroidogenesis inhibitor, FDA approved 2020). Pasireotide is the only somatostatin analog with the indication and the only pituitary-targeted medical therapy available.